# TB-500 Legal Status, FDA 503A Category, and Compounding Access > TB-500 legal status: FDA placed the thymosin beta-4 LKKTETQ fragment (TB-500) in 503A Category 2 (effective Sept 29, 2023). Not FDA-approved; WADA-prohibited. Access is under active FDA review. What is true right now, stated present-tense and cited to FDA — and where access is under active review, with the momentum hedged exactly as the record requires. ## TB-500 legal status: the current FDA fact TB-500 legal status begins with one present-tense FDA fact. FDA lists the substance as 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' and placed it in 503A 'Category 2' — bulk substances FDA has identified as potentially presenting significant safety risks — effective with FDA's September 29, 2023 nominated-substances update, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information [17]. FDA's own list entry establishes the identity relationship: TB-500 is the LKKTETQ fragment associated with thymosin beta-4 [17]. Two consequences follow directly from Category 2 status. As a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding — the policy that applies to Category 1 substances does not cover it [18]. And it is not an FDA-approved drug; TB-500 has no approved therapeutic indication of any kind [17]. Those two points — Category 2, and not FDA-approved — are the fixed coordinates of the current status. Everything that follows on this page is read against them. This is the [TB-500 legal status and FDA 503A](/legal-status) position as it stands today, cited to FDA pages verified to contain these entries. ## Is TB-500 FDA Approved? No. TB-500 is not FDA approved, and it has no FDA-approved therapeutic indication [17]. It is important to keep two separate regulatory questions apart. FDA approval of a finished drug — through a New Drug Application or Biologics License Application — is one question; whether a bulk substance may be used in compounding under the 503A/503B framework is a different question entirely [18]. TB-500 fails the first outright: there is no approved TB-500 medicine. Under the compounding framework, a bulk drug substance may be used in 503A compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; substances not on that list are evaluated by FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee (PCAC) [18]. TB-500 is in Category 2 within that process, which is the opposite of eligible: FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance [18]. So on both axes the answer is the same. TB-500 is not an approved drug, and as a Category 2 bulk substance it is not within the enforcement-discretion policy for routine 503A compounding while that status stands [18]. ## Access is under active FDA review — and may expand in 2026 The forward-leaning fact is real, and it is specific. TB-500 — listed by FDA as 'TB-500 (free base)' and 'TB-500 acetate' — is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026 as a bulk drug substance 'being considered for inclusion on the 503A Bulks List' [19]. The same agenda lists BPC-157, KPV, and MOTs-C. Access to compounded TB-500 is therefore under active FDA review and may expand in 2026. The hedge is non-negotiable, and it is exact. A PCAC meeting is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in current status; PCAC's role is advisory, and inclusion on a final bulks list is decided by FDA rulemaking, not by a committee discussion [18][19]. Being discussed by PCAC is a step in evaluation, not an outcome — and the outcome of the July 2026 meeting is unknown and is not assumed, stated, or dated here. What is current, then, is Category 2 status. What is scheduled is a discussion. The momentum is genuine; the result is not yet written. We state both, and we do not collapse the second into the first. ## What has not been confirmed Several claims circulate that we do not adopt, because they cannot be confirmed from an authoritative FDA source. Some commercial and clinic sources reported that in early 2026 roughly 14 of the peptides placed in Category 2 in 2023 were expected to move back toward Category 1; the most candid of those sources notes FDA had 'not yet published its formal updated list' and that 'the formal reclassification is still pending.' That could not be confirmed as a completed, effective FDA action, so it is not treated as having occurred. Likewise, some vendor and clinic pages assert specific 2026 dates on which substances were 'removed' from Category 2. Those dated removal claims could not be verified from an authoritative FDA source and are excluded here. Notably, the fact that the FDA PCAC agenda still lists TB-500 as 'being considered for inclusion on the 503A Bulks List' for July 2026 is consistent with its evaluation being ongoing rather than resolved [19]. The rule we hold to is the FDA's own copy guidance for this material: present-tense facts only, no future FDA action stated as fact or attached to a date, and any predicted reclassification framed strictly as an unconfirmed report of a pending matter. The last FDA action confirmable from FDA.gov is Category 2 placement, so that is the status we state. ## How legally compounded peptide access works In general terms — and this is general information, not medical or legal advice, and not an offer to supply anything — a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [18]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility [18]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It does not change which substances are eligible to be compounded, and it does not remove the requirement for a legitimate prescriber-patient relationship and a valid prescription [18]. It is a route to a consultation, not a separate legal status. The ingredient-eligibility caveat is what governs TB-500 specifically. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list [18]. A Category 2 substance that FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [18]. This page describes the landscape; it names no pharmacy, clinic, or provider, gives no dosing, and offers no way to obtain any substance outside that framework. ## Is TB-500 banned by WADA? Yes. TB-500 — and thymosin beta-4 — fall under World Anti-Doping Agency prohibited peptide and growth-factor and tissue-repair categories, and are banned both in and out of competition for the relevant classes. The substance is detected by LC-MS anti-doping assays in both equine and human matrices, and it has been encountered as a designer drug in racehorses, which prompted the development of equine and human detection methods. This is a separate regime from FDA compounding status, and it points the same direction: TB-500 is not an approved medicine in the U.S. [17], it is not within enforcement-discretion for routine 503A compounding as a Category 2 substance [18], and it is prohibited in sport by WADA. In some jurisdictions it is also classified as a prescription medicine. For anyone subject to anti-doping rules, the practical reading is simple: TB-500 is prohibited, and it is testable. The regulatory and the sport frameworks agree on the boundary even though they exist for different reasons. ## Access and regulatory questions These three appear inline here and on the FAQ index. --- A fiduciary-grade reading of the TB-500 and thymosin beta-4 record — each finding weighed against its own study and graded for evidence, the fragment-versus-protein line drawn in plain sight, with no clinic, pharmacy, or prescription behind the desk and nothing here dispensed or for sale.